Llwytho...

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF

BACKGROUND: Although oncogenic driver mutations were thought to be mutually exclusive in non‐small cell lung cancer (NSCLC), certain tumors harbor co‐occurring mutations and represent a rare molecular subtype. The evaluation of the clinical features and therapeutic response associated with this NSCL...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Med
Prif Awduron: Zhuang, Xibin, Zhao, Chao, Li, Jiayu, Su, Chunxia, Chen, Xiaoxia, Ren, Shengxiang, Li, Xuefei, Zhou, Caicun
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2019
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6558647/
https://ncbi.nlm.nih.gov/pubmed/31016879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2183
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!